Auris Medical's Keyzilen fails study

Auris Medical Holding (Nasdaq: EARS) reported disappointing results from a TACTT2 trial of its acute inner ear tinnitus treatment Keyzilen and reported a loss of for the second quarter. The stock price plunged $3.20 to close at $2.15.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.